Companies
Galapagos Inks Deal With Catalent to Use New Jersey Site for Decentralized Cell Therapy Trials
The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Guardant Health Reveal Assay Gets Additional Medicare Coverage for CRC Surveillance Testing
The test was previously covered for use in colorectal cancer patients in the early postsurgical setting only.
Jan 15, 2025
Jan 15, 2025
Jan 15, 2025
Jan 14, 2025